Claim · 2021 · event · Stated in source · Supported

Roche’s Annual Report 2021 states that Genentech “recently acquired Prescient Design”; a Genentech story of 2 November 2021 states that the Prescient Design team joined Genentech in August 2021 as a new department.

One recorded claim. The claim panel gives its qualification, the source passages with their place in each source, and how it was checked.

What it connects

Genentech → acquired → Prescient Design

Where it appears

No collection page holds this claim. It is listed with its records in the explorer.

Claim and evidence

Genentechacquired ↓Prescient Design

Machine-checked, not reviewed by an editorStated in sourceSupported

Supporting evidence: primary · 2 sources

Date: 2021 · event Records dated 2021 →

Scope and limitsRoche’s and Genentech’s own accounts; no price, terms or closing date are stated (maintainer decision of 2026-10-30, after the cross-family check located the annual report). The Genentech story is recorded by paraphrase because its text is carried in script data that the quotation check cannot read.

The evidence 02

primary sourceSupports the claim

Making Big Moves and Large Molecules (Genentech story on Prescient Design)

Genentech · 2021-11-02

Cite the original source

Cite the original document, not Selekoa. Check these details against it.

Paraphrase

The story says the goal of using machine learning to enhance antibody discovery led to Genentech's recent acquisition of Prescient Design, a company that originated in New York City and focuses on applying machine learning to protein design; it adds that the Prescient Design team joined Genentech in August 2021 as a new department.

Location in source article body (embedded page data), paragraphs 3 and 6

How it was read Retrieved directly from the publisher

Machine-checked · 2026-10-30

Source details and check notes

Authors: Genentech
Version: Retrieved for the candidate pack on 2026-10-30 (SHA-256 5ea1f26774e3091158f56ff07a63c97a91881d0f972400fe8cd9cfec96782a14). gene.com/stories page as served on 2026-10-30; the article text is carried in the page's embedded script data, not in the text tools.mjs extracts, so it is cited by paraphrase; the embedded metadata gives published_at 2021-11-02. Its wording can change; earlier wording is not authenticated.
Canonical address: Open the canonical source ↗
Accessed: 2026-10-30
Language: English (en)
Attribution: Genentech, “Making Big Moves and Large Molecules (Genentech story on Prescient Design)”, 2021-11-02.
Reuse: No open redistribution licence asserted. Bibliographic metadata, editorial paraphrases and short attributed quotations (at most 50 words each). Recheck terms before wider redistribution.
Check notes: Candidate pack passage, AI in biology (research/ai-in-biology). The paraphrase is Selekoa’s, written from the text retrieved for the candidate pack on 2026-10-30; it is not a quotation and was not machine-matched. Wording read in the page's embedded JSON as served on 2026-10-30; the earlier wording is not independently attested. A cross-family machine check (2026-10-30, item A15) answered the record’s question blind from fresh retrievals and agreed with the record. No human editorial review.

primary sourceSupports the claim

Roche Annual Report 2021

F. Hoffmann-La Roche Ltd · Publication date unknown

Cite the original source

Cite the original document, not Selekoa. Check these details against it.

Source excerpt

“Genentech recently acquired Prescient Design, which will support the application of ML to the optimisation and de novo design of therapeutic antibodies.”

Location in source PDF p. 55 (printed p. 53), paragraph on machine learning in research

How it was read Retrieved directly from the publisher

Machine-checked · 2026-10-31

Source details and check notes

Authors: Roche
Version: PDF of the Annual Report 2021 (202 pages), retrieved directly at admission on 2026-10-31 (SHA-256 0b1d00c04c43762c36cfa2a8949269c7752f37ccb9b9b56a40b2c866a8c798ae, the same bytes the cross-family check of 2026-10-30 reported). The retrieved text states no publication date; the PDF’s metadata gives a creation date of 31 January 2022.
Canonical address: Open the canonical source ↗
Accessed: 2026-10-31
Language: English (en)
Attribution: Roche, “Roche Annual Report 2021”.
Reuse: No open redistribution licence asserted. Bibliographic metadata, editorial paraphrases and short attributed quotations (at most 50 words each). Recheck terms before wider redistribution.
Check notes: Added at the admission of the AI in biology pack (research/ai-in-biology). Located by the cross-family machine check of 2026-10-30 and adopted as evidence by the maintainer’s decision of 2026-10-30; the report is the parent company’s own account. The quotation (22 words) matched a direct retrieval of 2026-10-31 (SHA-256 0b1d00c04c43762c36cfa2a8949269c7752f37ccb9b9b56a40b2c866a8c798ae). Matching ignored differences of whitespace, case, quotation marks and dashes. No human editorial review.

Status and meaning

Editorial status. Not reviewed by an editor. An exploratory record that no editor has accepted. This status does not say whether a person has read any linked passage. Each evidence record above shows how it was checked.

Relation. An acquisition of the named organisation, with timing and scope qualified by the evidence. Distinct from an internal reorganisation or team combination.

Date. Year of the acquisition as Roche’s Annual Report 2021 reports it (“recently acquired”); no closing date is stated. Genentech’s story dates the team’s joining to August 2021, which is not a documented closing date.

Record ID aib-co-genentech-acquired-prescient-2021